Literature DB >> 26693960

Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity.

David R Owen1, David M Wood2,3, John R H Archer2, Paul I Dargan4,5.   

Abstract

INTRODUCTION AND AIMS: There has been a global increase in the availability and use of novel psychoactive substances (NPS) over the last decade. Phenibut (β-phenyl-γ-aminobutyric acid) is a GABAB agonist that is used as an NPS. Here, we bring together published scientific and grey information sources to further understand the prevalence of use, desired effects and acute toxicity of phenibut. DESIGN AND METHODS: Using European Monitoring Centre for Drugs and Drug Addiction Internet snapshot methodology, we undertook an English language Internet snapshot survey in May 2015 to gather information on the availability and price of phenibut from Internet NPS retailers. To gather information on prevalence of use, desired effects and/or adverse effects, we searched grey literature (online drug discussion forums) and medical literature (PubMed and abstracts from selected International Toxicology conferences).
RESULTS: We found 48 unrelated Internet suppliers selling phenibut in amounts ranging from 5 g (US$1.60, £1.01/g) to 1000 kg (US$0.23, £0.14/g). Capsules containing 200-500 mg of phenibut were available in packs of between 6 (US$4.45, £2.80/g) and 360 (US$0.43, £0.27/g). According to the grey literature, phenibut is taken for its anxiolytic and euphoric properties, with tolerance and withdrawal syndromes commonly reported adverse effects. Phenibut is taken orally at an average dose of 2.4 g. Case reports in the medical literature feature users who present to emergency departments heavily sedated or experiencing withdrawal. There have been no reported deaths relating to phenibut use. DISCUSSION AND
CONCLUSIONS: Phenibut is readily available in the UK from Internet sites selling NPS. Its desired and adverse effects appear similar to other gamma-aminobutyric acid receptor agonists. [Owen DR, Wood DM, Archer JRH, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev 2016;35:591-596].
© 2015 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Keywords:  GABA; GABAB; NPS; acute toxicity; availability; phenibut; prevalence of use; recreational drug

Mesh:

Substances:

Year:  2015        PMID: 26693960     DOI: 10.1111/dar.12356

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  9 in total

1.  Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report.

Authors:  Yash B Joshi; Samantha F Friend; Berenice Jimenez; Louisa R Steiger
Journal:  J Clin Psychopharmacol       Date:  2017-08       Impact factor: 3.153

Review 2.  Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable "Dietary Supplement" With Propensities for Physical Dependence and Addiction.

Authors:  Edward A Jouney
Journal:  Curr Psychiatry Rep       Date:  2019-03-09       Impact factor: 5.285

3.  An Unusual Presentation of an Uncommon Drug: A Case Report on Phenibut Overdose.

Authors:  Christopher D Nedzlek; Anthony Michaelis
Journal:  Cureus       Date:  2022-04-07

4.  The Psychonauts' World of Cognitive Enhancers.

Authors:  Flavia Napoletano; Fabrizio Schifano; John Martin Corkery; Amira Guirguis; Davide Arillotta; Caroline Zangani; Alessandro Vento
Journal:  Front Psychiatry       Date:  2020-09-11       Impact factor: 4.157

5.  When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use.

Authors:  Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein
Journal:  Am J Drug Alcohol Abuse       Date:  2021-04-28       Impact factor: 3.912

6.  Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse.

Authors:  Tania Ahuja; Ofole Mgbako; Caroline Katzman; Allison Grossman
Journal:  Case Rep Psychiatry       Date:  2018-04-30

7.  Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019.

Authors:  Janessa M Graves; Julia Dilley; Sanjay Kubsad; Erica Liebelt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-09-04       Impact factor: 17.586

8.  Phenibut Addiction in a Patient with Substance Use Disorder.

Authors:  Kan Hong Zheng; Afra Khan; Eduardo D Espiridion
Journal:  Cureus       Date:  2019-07-24

Review 9.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.